Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 674

1.

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J.

Ophthalmology. 2011 Dec;118(12):2453-60. doi: 10.1016/j.ophtha.2011.05.014. Epub 2011 Jul 20.

PMID:
21764136
2.

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group.

Ophthalmology. 2010 Jun;117(6):1134-1146.e3. doi: 10.1016/j.ophtha.2010.03.032. Epub 2010 Apr 24.

PMID:
20417567
3.

Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.

Mayer WJ, Remy M, Wolf A, Kook D, Kampik A, Ulbig M, Reznicek L, Haritoglou C.

Ophthalmologica. 2012;228(2):110-6. doi: 10.1159/000338732. Epub 2012 Jun 23.

PMID:
22739239
4.

Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study).

Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA.

Retina. 2014 Feb;34(2):342-51. doi: 10.1097/IAE.0b013e318297f842.

PMID:
23846381
5.

Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant.

Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, Whitcup SM, Kowalski JW.

Ophthalmology. 2012 Jun;119(6):1190-8. doi: 10.1016/j.ophtha.2011.12.028. Epub 2012 Feb 22.

PMID:
22361318
6.

Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study.

Dugel PU, Capone A Jr, Singer MA, Dreyer RF, Dodwell DG, Roth DB, Shi R, Walt JG, Scott LC, Hollander DA; SHASTA Study Group.

BMC Ophthalmol. 2015 Sep 4;15:118. doi: 10.1186/s12886-015-0106-z.

7.

Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.

Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li XY, Hollander DA, Schiffman RM, Whitcup SM; Ozurdex PLACID Study Group.

Ophthalmology. 2013 Sep;120(9):1843-51. doi: 10.1016/j.ophtha.2013.02.018. Epub 2013 May 22.

PMID:
23706947
8.

Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion.

Kuppermann BD, Haller JA, Bandello F, Loewenstein A, Jiao J, Li XY, Whitcup SM.

Retina. 2014 Sep;34(9):1743-9. doi: 10.1097/IAE.0000000000000167.

PMID:
24830824
9.

Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.

Korobelnik JF, Kodjikian L, Delcourt C, Gualino V, Leaback R, Pinchinat S, Velard ME.

Graefes Arch Clin Exp Ophthalmol. 2016 Dec;254(12):2307-2318. Epub 2016 Jun 11.

10.

Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study.

Li X, Wang N, Liang X, Xu G, Li XY, Jiao J, Lou J, Hashad Y; China Ozurdex in RVO Study Group.

Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):59-69. doi: 10.1007/s00417-017-3831-6. Epub 2017 Nov 8.

11.

Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.

Blanc J, Deschasse C, Kodjikian L, Dot C, Bron AM, Creuzot-Garcher C.

Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1441-1448. doi: 10.1007/s00417-018-4016-7. Epub 2018 May 31.

PMID:
29855706
12.

Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results.

Jain N, Stinnett SS, Jaffe GJ.

Ophthalmology. 2012 Jan;119(1):132-7. doi: 10.1016/j.ophtha.2011.06.019. Epub 2011 Sep 14.

PMID:
21924503
13.

Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.

Eter N, Mohr A, Wachtlin J, Feltgen N, Shirlaw A, Leaback R; German Ozurdex in RVO Real World Study Group.

Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255(1):77-87. doi: 10.1007/s00417-016-3431-x. Epub 2016 Jul 26. Erratum in: Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255 (1):89.

14.

OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS.

Reid GA, Sahota DS, Sarhan M.

Retina. 2015 Aug;35(8):1647-55. doi: 10.1097/IAE.0000000000000524.

PMID:
25932545
15.

Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group.

Ophthalmology. 2014 Oct;121(10):1904-14. doi: 10.1016/j.ophtha.2014.04.024. Epub 2014 Jun 4.

16.

Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.

Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland J, Stene-Johansen I.

Am J Ophthalmol. 2010 Sep;150(3):310-4. doi: 10.1016/j.ajo.2010.03.028. Epub 2010 Jun 29.

PMID:
20591399
17.

Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.

Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A.

Ophthalmology. 2012 Dec;119(12):2587-91. doi: 10.1016/j.ophtha.2012.06.037. Epub 2012 Aug 17.

PMID:
22902212
18.

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG.

Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29.

PMID:
21715011
19.

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators.

Ophthalmology. 2010 Jun;117(6):1124-1133.e1. doi: 10.1016/j.ophtha.2010.02.022. Epub 2010 Apr 9.

PMID:
20381871
20.

Efficacy and Safety of Dexamethasone Intravitreal Implant for Treatment of Refractory Macular Edema Secondary to Retinal Vein Occlusion in Taiwan.

Sheu SJ, Wu TT, Horng YH.

J Ocul Pharmacol Ther. 2015 Oct;31(8):461-7. doi: 10.1089/jop.2014.0119. Epub 2015 Jun 11.

PMID:
26067779

Supplemental Content

Support Center